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ABSTRACT
Molecular Mechanisms of Chromium (VI) - Induced Toxicity and
Carcinogenesis
DJORDJE MEDAN
Cr(VI) compounds are redox cycling carcinogens that induce apoptosis as a
primary mode of cell death. Since defects in apoptosis regulatory mechanisms
are considered to be indispensable foundation of carcinogenesis it is critical to
understand the molecular effectors involved. Cellular energy powerhouses, the
mitochondria, house the effectors involved in signaling cascades comprising
commitment to apoptosis and are reported to be dysregulated in variety of
tumors. The objective of this study was to characterize the key signaling effectors
in Cr(VI)-induced apoptosis and determine the relationship between those
effectors and mode of cellular energy production in cancerous vs. non-cancerous
cells. Our data show that Cr(VI) induced mitochondrial ROS dependent apoptosis
in human lung cancer (H460) and non-cancerous (BEAS-2B) cells. The intensity
of mitochondrial ROS production and consequently apoptosis was highly
dependent on the energy substrate available to the cells. Forcing of oxidative
phosphorylation-only energy metabolism abrogated apoptosis resistance in
cancerous H460 cells vs. non-cancerous BEAS-2B cells. Collectively, these
findings present a mechanistic advancement in the understanding of molecular
effectors underlying the Warburg’s “mitochondrial dysregulation” hypothesis and
put mitochondrial ROS as key mediators causal agents of the commitment phase
of programmed cell death in a model of Cr(VI)-induced toxicity. In addition, longterm exposure to Cr(VI) leads to malignant transformation of human lung
epithelial BEAS-2B cells, as indicated by their increased cell migration, invasion,
proliferation, and colony formation activities. Cr(VI)-transformed cells induced
tumorigenesis in nude mice comparable to that of well established human lung
cancer H460 cells, whereas passage-matched control BEAS-2B cells showed no

	
  

	
  

tumor development. To provide a mechanistic insight to the tumorigenic process,
stable knockdown mutants of Cr(VI)-transformed cells and H460 cells exhibiting
downregulated Bcl-2 phenotype were generated and evaluated for tumor
associated properties in vitro and in vivo. The Bcl-2 knockdown mutants showed
a substantial decrease in the rates of colony formation, invasion, migration and
proliferation, as well as tumor formation in mice, in comparison to vector controls.
These results indicate a novel role of Bcl-2, beyond apoptosis regulation, to be a
key regulator of malignant transformation and tumorigenesis in vivo. The model
described here may provide utility to other xeno-carcinogenesis studies, including
those of heavy metals which currently lack effective in vivo tumor development
experimental means.
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CHAPTER I
Background and Objectives
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1.1 The Warburg Paradox
Ever since Otto Warburg’s 1930 observation that cancer cells prefer to derive
energy from anaerobic glycolysis as opposed to, energetically speaking, much
more efficient oxidative phosphorylation (Figs. 1-2), elucidation and confirmation
of molecular mechanisms underlying this apparent anomaly have been
underway. Although the glycolytic phenotype of many cancer cell lines and
tumors has been demonstrated at biochemical and molecular levels (1-3), the
‘Warburg’ hypothesis of mitochondrial function impairment (4) has not been
established in cancer biology. In fact, some 80 years later, we continue to seek
biochemical and molecular biology evidence of mitochondria’s role, and its
extent, in neoplastic transformation and in maintenance and/or promotion of
neoplasia. Over the past two decades, our energy reactors have taken a center
stage at another process central to neoplasia – programmed cell death.
Following Andrew Wylie’s 1972 observation on the significance of natural cell
death in mammary gland tissue, coined apoptosis, efforts to understand its
molecular effectors have taken a center stage in countless laboratories around
the world. Today, we know that apoptosis is an ‘active’ process indispensable to
support of normal physiological processes from embryonic development to
maintenance of tissue homeostasis via preservation of genomic and phenotypic
integrity. If the cell(s) is damaged beyond repair (i.e. xenobiotic-induced toxicity),
intrinsic apoptotic pathway is activated. If the outside system (i.e. tissue, immune
surveillance) deems the cell(s) undesirable, extrinsic pathway is activated.
Regardless of whether intrinsic or extrinsic, the sequence of events can be
summarized as: Signal Initiation, Cellular Apoptosis Commitment, and Apoptosis
Execution. Finally, the cell’s remnants are packaged into vesicles (apoptotic
bodies) and recycled by its microenvironment. Each of the three stages is
regulated by a different subset of molecular effectors with different localization.
According to prevailing current evidence, mitochondrial level signaling cascades
constitute the ‘Commitment’ stage – mitochondria decide whether the cell dies or
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not. Specifically, release of cytochrome c from the mitochondrial intermembrane
space is generally accepted to be the molecular point of no return.
In molecular cancer research, multiple lines of evidence and reason suggest that
“one renegade cell” must evade a program entrusted with maintenance of
genomic and phenotypic integrity, in order to uncontrollably divide and ultimately
conquer the host, remarkably similar to our early ancestors - the bacteria. In
addition to the central role in early carcinogenic events, further dysregulation of
apoptotic signaling cascades is strongly implicated in phenomenon of multi-drug
resistance. If Warburg was correct, and mitochondrial dysregulation is a
defining feature of cancer, as supported by autonomy via apoptosis
inactivation (gain of function), is there a molecular rationale (i.e. signaling
link) to apparent loss of function via reliance on net-energy inefficient
glycolysis amidst massive energy needs? This was a central question
preoccupying most of the cerebral bandwidths of a young graduate student,
yours truly, embarking onto his PhD journey. What experimental model could
shed light on the link? Enter Chromium (VI).
1.2. Chromium exposure
Hexavalent chromium [Cr(VI)] compounds are known environmental
contaminants and human occupational respiratory carcinogens mostly originating
from industrial processes (5). While the primary route of exposure is inhalation,
additional modes include oral ingestion via contaminated water, or by direct
dermal contact with products manufactured using chromium (6). The
environmental release of chromium is estimated at over 90,000,000 pounds
annually (7). For example, the burning of one cigarette releases up to 0.5 µg of
chromium. It is estimated that the atmospheric concentration of particulate
chromates in rural or residential areas of the U.S. ranges from 0.2 to 9 ng/m3 (7).
In urban areas, especially in areas with a ferrochrome industry presence, those
concentrations can easily be 10–100 fold higher (8). If one assumes that an
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urban dweller in a city with a ferrochrome production facility receives an
inhalation exposure of 20 m3 per day of 90 ng/m3, then the daily lung intake is 1.8
µg/day. Epidemiological studies carried out in the U.K., Europe, Japan and the
U.S. have consistently shown that workers in occupations where particulate
chromates are generated or used have an elevated risk of respiratory disease
including lung cancer (9,10). Chromate workers have been found to have marked
lung burdens of chromium with lung concentrations up to and exceeding 10,000
µg chromium per 100 g wet weight (11,12). Taken together, extensive studies
and data collection on the industrial and environmental exposure to chromium
compounds have led the National Institute of Occupational Safety and Health
(NIOSH) to list chromate compounds as one of the major causes of occupational
lung cancer, and the U.S. Environmental Protection Agency (U.S. EPA) and the
International Agency for Research on Cancer (IARC) to classify chromium as a
human carcinogen, currently making Cr(VI) one of 33 compounds listed to pose
the greatest potential health threat in urban areas (6,13–15).
1.3. Chromium metabolism
Chromium is a transition-group metal that has several oxidation states (6). Under
physiological pH and temperature, Cr(VI) is unable to interact with DNA and
lacks genotoxic activity (20). The structural similarity of chromates to
physiological sulfates and phosphate ions, enables molecular mimicry and easy
entry of Cr(VI) into cells through non-specific anion channels (Fig. 3) (19,21).
Cr(VI) enters the cell as an oxyanion followed by its metabolic reduction to Cr(V),
Cr(IV), and to the final reduced trivalent (III) form. These reduced forms have
been shown to induce a wide range of genomic DNA damage, which may lead to
DNA replication inhibition (22). At physiological pH, intracellular reduction is
facilitated by several molecules/compounds such as ascorbate, glutathione
(GSH), cysteine, lipoic acid, hydrogen peroxide, NAD(P)H, fructose and ribose
(16,18-20,23). The respective cellular availability and reaction rate with Cr(VI)
determines which is the primary reducing agent. GSH, which is highly abundant
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intracellularly and found at millimolar concentrations, has been identified as a
modulator of cell stress induced by Cr(VI) cytotoxicity. Upon GSH depletion,
Cr(VI) induces an overexpression of heme-oxygenase 1 in human dermal
fibroblasts, which has been used as a marker for Cr(VI)-induced cell stress and
cytotoxicity (24). The final product of chromate reduction, Cr(III), is biologically
stable and has a greater DNA binding efficiency than that of Cr(VI) (16). Notably,
extracellular reduction of Cr(VI) to Cr(III) detoxifies the molecule due to the
inability of Cr(III) to cross the cellular membrane. However, when Cr(VI) is
reduced in the cell to Cr(III), the weak membrane permeability of the trivalent
form intracellularly traps the molecule, enabling the formation of stable Cr(III)
complexes with proteins and nucleic acids leading to a large spectrum of DNA
damage (19).
1.4. Chromium-induced oxidative stress
The reduction of Cr(VI) has been shown to yield reactive species such as free
radicals, superoxide anions and hydroxyl radicals, possibly through Fenton-like
reactions of Cr(V) and Cr(IV) with hydrogen peroxide (18,25). Several electron
spin resonance (ESR) spin trapping studies have shown the generation of
hydroxyl radicals in conjunction with long-lived Cr(V) species, following the
reduction of Cr(VI) by NADPH and glutathione (25–35). While the direct
relationship between DNA-reactive oxygen species and chromium-induced DNA
damage is heavily debated and unclear, there have been several studies
supporting the role of ROS in Cr(VI)-induced genotoxicity, cytotoxicity, and
oxidative stress (17,35–39). To date, many studies have attempted to investigate
the complexities of Cr(VI)-mediated oxidative stress and damage. Sugiyama et
al. have shown Cr(VI) can be reduced to Cr(V) in the presence of vitamin B2
(riboflavin) in Chinese hamster V79 cells, leading to an increase in hydroxyl
radicals, chromosomal aberrations and mutations at the HGPRT locus (37,40).
Moreover, when pretreated with flavin adenine dinucleotide or vitamin E (a free
radical scavenger), there was a marked decrease in Cr(VI)-induced single-strand
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breaks and cytotoxicity (41). Other in vitro studies have shown that antioxidant
regulation may be dependent on the concentration of Cr(VI). Asatiani et al.
demonstrated in human epithelial like L-41 cells and fetal human lung fibroblasts,
that toxic Cr(VI) concentrations (20 µM) lead to an increase in ROS, and a
significant reduction in catalase, glutathione, and cytosolic Cu/Zn superoxide
dismutase activity (42). In contrast, there was a marked increase in catalase and
glutathione peroxidase activity following non-toxic doses of Cr(VI) (2 µM),
demonstrating the existence of thresholds to Cr(VI)-induced oxidative stress.
Furthermore, many reports studying Cr(VI)-mediated oxidative stress investigate
its effect on cell death, or apoptosis. A study by Shi et al. suggests that ROS
contributes to the early effects of Cr(VI)-induced apoptosis via a p53-independent
mechanism, whereas the apoptotic effects could be blocked in the presence of
ROS scavengers, such as catalase, aspirin and N-acetyl-l-cysteine (35). Bagchi
et al. have also shown an increase in ROS production that correlates with
apoptotic death in a Cr(VI) concentration and dose-dependent fashion (43).
Although there are many studies reporting on the relationship between oxidative
stress and Cr(VI)-mediated cytotoxicity, genotoxicity, and potential
carcinogenesis, due to non-uniform treatment protocols, conflicting data and
controversial methods used for detection of Cr(VI)-induced oxidative stress, this
relationship remains unclear. Martin et al. demonstrated that the high valence
chromium species, bis(2-ethyl-2hydroxybutyrato) oxochromate (V) [Cr(V)-EHBA],
was able to independently induce the fluorescence of two dyes commonly used
to detect ROS (2,7-dichlorofluorescin and dihydrorhodamine) in A549 cells,
which was not affected by treatment with radical scavengers (44). These data
suggest that 2,7-dichlorofluorescin and dihydrorhodamine are more suitable for
the qualitative detection of Cr(V), rather than ROS production in the presence of
Cr(VI). Moreover, it is likely that any discussion on the potential role of Cr(VI)induced oxidative stress needs to include careful consideration of total dose over
time and dose rate, as well as the relative ratios and availability of intracellular
reductants and anti-oxidants. Given the intricate and unclear relationship
between apoptosis and oxidative stress, it will be very difficult to determine
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whether Cr(VI)-associated oxidative stress is caused by, or causes, the initiation
of apoptosis.
1.5. Cr(VI)-induced DNA damage and mutagenesis
Chromium-induced DNA damage is thought to be the primary mechanism of
chromate genotoxicity and mutagenicity, but it is only clearly observed at doses
that are also capable of producing cell death (45). Recently, data has been
presented to the EPA’s Cancer Assessment Review Committee (CARC) to
support mutagenicity as the initiating step in Cr(VI)-induced carcinogenesis (46).
Structural genetic lesions produced by Cr(VI) include DNA adducts, DNA-strand
breaks, DNA–protein crosslinks, oxidized bases, abasic sites, and DNA interand intrastrand crosslinks (20,47). The association of chromium with the
phosphodiester backbone of DNA (chromium–DNA adduct) is one of the most
abundant genetic lesions induced by chromium in mammalian cells and is
thought to be a primary cause of Cr(VI) mutagenicity (19). Cr(III)–ligand–DNA
complexes form binary and ternary adducts, the latter of which are predominant
and more toxicologically relevant (19,20). There are four types of ternary adducts
that primarily persist following Cr(VI) exposure and intracellular reduction; they
are Cr(III)–ascorbate–, Cr(III)–cysteine–, Cr(III)–histadine–, and Cr(III)–
glutathione–DNA adducts, respectively (19).
Mutational analysis studies using SV-40 immortalized human fibroblasts
transfected with plasmids extracellularly treated with Cr(VI), showed that the
primary and most mutagenic adduct formed was ternary in nature, and that the
Cr(III)–cysteine–DNA and Cr(III)–ascorbate–DNA adducts were more mutagenic
than the binary adducts (48,49). O’Brien et al. showed significant DNA damage in
the form of DNA–chromium–DNA crosslinks and DNA–chromium–GSH
crosslinks following treatment of DNA with Cr(III) and Cr(VI) with ascorbate and
GSH, respectively (22). The damage induced by Cr(VI) can lead to dysfunctional
DNA replication and transcription causing base substitutions and deletions
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serving as substrates for base excision repair (BER) and nucleotide excision
repair (NER), and promoting genomic instability (50). Genomic instability, which
can be caused by aberrant cell cycle checkpoints and dysregulated DNA repair
mechanisms via microsatellite instability (MIN), plays an important role in Cr(VI)
carcinogenesis (48). There are several lines of evidence suggesting the
importance of base substitutions in Cr(VI) mutagenicity, with G:C substitutions
shown to be the primary target in vitro and in vivo; however, studies supporting
the relevance of specific Cr(VI)-induced base deletions are inconsistent (48).
Furthermore, mechanistic studies in Cr(VI)-induced toxicity and mutagenesis are
lacking a focal point of mitochondria.
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FIGURE 1. Schematic Representation of Cellular Energy Metabolism.
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FIGURE 2. Diagrammatic Illustration of Oxidative Phosphorylation Pathway.

	
  

10	
  

FIGURE 3. Schematic representation of known cellular reduction and
cytotoxic effects of Cr(VI).
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1.6. Summary
A. Sustained environmental exposure to Cr (VI) compounds leads to a multitude
of respiratory illnesses including lung cancer. Lung cancers mostly manifests as
epithelial cell derived carcinomas. The process by which chromium is able to
induce neoplastic progression is both complex and fairly elusive. Data can be
found on each end of the spectrum, either supporting or refuting the many
mechanisms proposed in the involvement of Cr(VI) carcinogenesis. Given
phenotypic tissue diversity and considerable controversy surrounding
observations on Cr(VI)-mediated toxicity and mutagenesis, it is still unknown
whether, and to what extent, human lung epithelial cells are susceptible to Cr(VI)induced toxicity and carcinogenesis. This is largely due to the lack of an
appropriate model system to study the molecular mechanisms involved in Cr(VI)induced malignant transformation and carcinogenesis.
B. It is well established that the spectrum of cellular effects of Cr(VI) begins with
its intracellular metabolism, reactive oxygen species production, formation of Cr–
DNA adducts, genomic damage, and alteration of survival signaling pathways.
The causal early mechanistic events are accepted to be ‘chemical’ in nature, a
function of Cr and O2 chemistry. It is of no surprise therefore that little is known
about the role of mitochondrial physiology in cell’s ultimate fate.
C. Mitochondria lie at the center of two cellular processes fundamental to
evolution and maintenance of neoplasia – energy production and apoptosis. The
potential causal relationship between the two processes has proven to be elusive
despite rigorous scientific pursuit for almost 2 decades. The Warburg Paradox
remains one of the central questions in molecular cancer research.
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1.7. Specific Aims
Although Cr(VI) is an established human carcinogen, its mechanism of action
remains unclear. The overall objective of this study was to determine the
molecular mechanisms of Cr(VI)-induced apoptosis and malignant transformation
with the goal of improving our understanding on Cr(VI)-induced carcinogenesis.
To achieve this goal we accomplished the following specific aims:
Aim I: Establish a lung cancer relevant model to study the mechanisms of Cr(VI)induced toxicity and carcinogenesis.
Aim II: Identify molecular effectors underlying the cellular response to Cr(VI)induced stress with the focal point of mitochondria.
Aim III: Deduce experimental basis for reconciliation of the Warburg Paradox.
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CHAPTER II
Energy Substrate Modulates Cr(VI)-Induced Apoptosis
Differentially in Cancerous vs. Non-Cancerous cells via a
Mitochondrial Reactive Oxygen Species-Dependent Mechanism
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2.1 Abstract
Cr(VI) compounds are redox cycling carcinogens that induce apoptosis as a
primary mode of cell death. Since defects in apoptosis regulatory mechanisms
are considered to be indispensable foundation of carcinogenesis it is critical to
understand the molecular effectors involved. Cellular energy powerhouses, the
mitochondria, house the molecular effectors involved in signaling cascades
comprising commitment to apoptosis and are reported to be dysregulated in a
variety of tumors. The objective of this study was to characterize the key
signaling effectors in Cr(VI)-induced apoptosis and determine the relationship
between those effectors and mode of cellular energy production in cancerous vs.
non-cancerous cells. Our data show that Cr(VI) induces mitochondrial ROS
dependent apoptosis in human lung cancer (H460) and non-cancer (BEAS-2B)
cells. The intensity of mitochondrial ROS production and consequently apoptosis
is highly dependent on the energy substrate available to the cells. Forcing of
oxidative phosphorylation-only energy metabolism abrogates native 4-fold
apoptosis resistance in cancerous H460 cells vs. non-cancerous BEAS-2B cells.
Collectively, our report presents a mechanistic advancement in the
understanding of molecular effectors underlying the Warburg’s “mitochondrial
dysregulation” hypothesis and puts mitochondrial ROS as key mediators of the
commitment phase of programmed cell death in a model of Cr(VI)-induced
toxicity.
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2.2 Introduction
Mitochondria play an essential role in providing energy to the eukaryotic cell. In
recent years, mitochondria have become a central subject of study because of
their role as sensors and executioners of apoptosis (1–3). Apoptosis is an
energy-dependent, genetically encoded program for cell death that is
indispensable for the normal development of the organism (4). Alterations in the
cellular program of apoptosis contribute to the progression of various human
pathologies, including cancer and neurodegenerative diseases (5, 6). The study
of the energy metabolism of cancer cells was a central issue of cancer research
until the era of molecular biology. As early as 1930, Otto Warburg proposed the
hypothesis that cancer cells may have impaired mitochondrial function and that
this alteration would result in the elevated rate of glycolysis that is a common
feature of most tumors (7). Although the glycolytic phenotype of many cancer
cells and tumors has been demonstrated at both the biochemical and molecular
levels (8 –10), the presumed impairment of mitochondrial function was never
established in cancer biology (11). Differences in the number of mitochondria
(12), their ultrastructure (13, 14), the content and composition in all OXPHOS
complexes (12, 15–18), respiratory chain activity (18, 19), the expression of
oxidative phosphorylation dependent genes (20), and levels of mitochondrial
DNA (15) have all been variously reported by different investigators, but no
consistent pattern has emerged. When glucose is no longer available, as can
occur in solid tumors (21), cancer cells are forced to use alternative energy
substrates such as the oxidation of glutamine, a process called glutaminolysis
(22). This process requires an active oxidative phosphorylation for ATP
production. Here, we have examined the physiological effects of such a change
in substrate availability on a human lung cancer cell line (H460) vs. non-cancer
cell line (BEAS-2B) in a model of Cr(VI)-induced acute toxicity.
Inhalation of Cr(VI) compounds as dust particles and fumes is a common form of
exposure that can cause multiple respiratory effects including lung cancer (23,
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24,25–28). More than 300,000 workers in the United States are potentially
exposed to Cr(VI) and Cr(VI)-containing compounds in the workplace. Cr(VI)
enters cells through a non-specific anion transport system (29). Once inside, it is
reduced by cellular reductants to its lower oxidation states, pentavalent
chromium (Cr(V)) and tetravalent chromium (Cr(IV)) (30). The lower oxidation
intermediates of chromium are reactive and lead to production of reactive oxygen
species (ROS) (31, 32) which, in turn, cause various levels of oxidative damage
including DNA strand breaks, base modification and lipid peroxidation (30, 3337). Acute laboratory exposure generally results in cell death in the form of
apoptosis (38) or mutagenesis (39) depending largely on Cr(VI) dose and the
system used.
To date, specific molecular effectors constituting cellular response to acute Cr(VI)
stress remain poorly understood, especially at the level of mitochondria.
Furthermore, the effect of energy substrate modulation (glycolysis vs. oxidative
phosphorylation) has not been investigated in published Cr(VI) studies. Our study
is the first comprehensive analysis of the effect energy substrate plays in Cr(VI)induced acute toxicity in cancerous vs. non-cancerous cells. We identify
mitochondrial ROS as the primary agents of commitment phase of programmed
cell death and establish their quantitative dependence on cellular energetic
mode. Further, forcing of oxidative phosphorylation-only energy metabolism
abrogates native 4-fold apoptosis resistance in human lung cancer H460 cells vs.
their non-cancerous BEAS-2B counterparts. Collectively, our report presents a
mechanistic advancement in understanding of molecular effectors underlying the
Warburg’s “mitochondrial dysregulation” hypothesis and establishes a model for
further mechanistic studies of xeno-biotic toxicities.
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2.3 Materials and Methods
Chemicals and Reagents
N-acetyl cysteine (NAC), rotenone, diphenylene iodonium (DPI), sodium
pyruvate, buthionene sulfoximine (BSO), Tris-HCl, Triton X-100, NaCl, glycerol,
Na3VO4, NaF, phenylmethylsulfonyl fluoride (PMSF), bicinchoninic acid (BCA),
5,5-dimethyl-l-pyrroline N-oxide (DMPO), monochlorobimane (mBCl), glucose
and sodium dichromate (Na2Cr2O7.2H2O) [Cr(VI)] were obtained from Sigma
Chemical Inc. (St. Louis, MO). The spin trap DMPO was purified by charcoal
decolorization and vacuum distillation. DMPO solution, thus purified, did not
contain any electron spin resonance (ESR)-detectable impurities. Phosphatebuffered saline (PBS) and RPMI-1640 medium were purchased from Gibco BRL
(Gaithersburg, MD). Chelex 100 chelating resin was purchased from Bio-Rad
Laboratories (Richmond, CA). The phosphate buffer (pH 7.4) was treated with
Chelex 100 to remove transition metal ion contaminants. Hanks balanced salt
solution (HBSS) was purchased from Mediatech (Herndon, VA). Defined fetal
bovine serum (FBS) was purchased from Hyclone (Logan, UT). Apoptosis dye
Hoechst 33342 was purchased from Molecular Probes (Eugene, OR). Antibodies
for glutathione peroxidase, (GPx), manganese superoxide dismutase (MnSOD),
Bcl-2, peroxidase-labeled secondary antibodies, anti-myc agarose beads, and
protein A-agarose were from Santa Cruz Biotechnology (Santa Cruz, CA).
Transfecting agent Lipofectamine 2000 was from Invitrogen (Carlsbad, CA).
Cell Culture
The human lung bronchial epithelial BEAS-2B and human lung epithelial cancer
H460 cell lines were obtained from the American Type Culture Collection (ATCC)
(Rockville, MD). Cells were cultured in RPMI 1640 medium (Sigma, St. Louis,
MO) containing 5% fetal bovine serum, 2 mM L-glutamine, 100 units/ml penicillin
and 100 µg/ml streptomycin in a 5% CO2, standard atmosphere environment at
37°C. Cells were passaged at preconfluent densities using a solution containing
0.05% trypsin and 0.5 mM EDTA (Invitrogen). Energy substrate modulation
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studies were conducted in RPMI glucose-free medium containing 20 mM
pyruvate and 10 mM L-glutamine. The control media contained 20 mM glucose
instead of pyruvate. Cells were acclimated to the media at least 24 h prior to the
commencement of the experiments.
Apoptosis Assay
After specific treatments, apoptosis was determined by incubating cells with 10
µg/ml Hoechst 33342 nuclear stain for 30 min at 37°C and scoring the
percentage of cells having intensely condensed chromatin and/or fragmented
nuclei by fluorescence microscopy (Axiovert100, CarlZeiss) using Pixera
software.
Mitochondrial Membrane Potential (Δψm)
Δψm was estimated using 5,5’,6,6’-tetrachloro-1,1’,3,3’-tetraethylbenzimidazole
carbocyanide iodide (JC-1; Molecular Probes). JC-1 is a fluorescent compound
(excitation maximum, 490 nm) that exists as a monomer at low concentrations.
At higher concentrations, JC-1 forms aggregates. Fluorescence of the monomer
is green (emission, 527 nm), whereas that of the J aggregate is red (emission,
590 nm). Mitochondria with intact membrane potential (higher than 100 mV)
concentrate JC-1 into aggregates that fluoresce red, whereas de-energized
mitochondria cannot concentrate JC-1 and fluoresce green. Cells were grown in
25-cm2 dishes until 90% confluence and either kept in the medium alone (control)
or treated with 1 mM Cr(VI) for 1 h. Cells were washed with PBS and incubated
at 37°C for 45 min with 6.5 mM JC-1 in media in the dark. Cells were collected by
trypsinization, washed in PBS, and resuspended in 500 ml of PBS. The ratio of
the reading at 590 nm to the reading at 527 nm (590:527 ratio) was considered
as a relative Δψm value.
Stable Transfection
Stable transfectants of glutathione peroxidase (GPx), manganese superoxide
dismutase (MnSOD) and Bcl-2 were generated by culturing BEAS-2B and H460
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cells in six-well plates until they reached 80% confluence. 1 µg of
cytomegalovirus -neo vector and 15 µl of Lipofectamine 2000 reagent with 2 µg
of Bcl-2, GPx, MnSOD, or control pcDNA3 plasmid were used to transfect the
cells in the absence of serum. After 10 h, the medium was replaced with culture
medium containing 5% fetal bovine serum. Approximately 36 h after the
beginning of the transfection, the cells were digested with 0.03% trypsin, and the
cell suspensions were plated onto 75 ml culture flasks and cultured for 24 to 28
days with G418 selection (400 µg/ml). Stable transfectants were identified by
Western blot analysis and were cultured in G418-free RPMI 1640 medium for at
least two passages before each experiment.
Electron Spin Resonance ROS Assay
Spin trapping was used to detect short-lived free radical intermediates. This
technique involved the addition-type reaction of a short-lived radical with a
paramagnetic compound (spin trap) to form a relatively long-lived free radical
product (spin adduct), which was then studied using conventional ESR. All ESR
measurements were conducted using a Bruker EMX spectrometer (Bruker
Instruments, Inc., Billerica, MA) and a flat cell assembly. The intensity of the
signal was used to measure the amount of short-lived radicals trapped; the
hyperfine couplings of the spin adduct were generally characteristic of the
original trapped radicals. Hyperfine couplings were measured (to 0.1 G) directly
from magnetic field separation using potassium tetraperoxochromate (K3CrO8)
and 1,1-diphenyl-2-picrylhydrazyl (DPPH) as reference standards. The relative
radical concentration was estimated by multiplying half of the peak height by
[ΔHpp], where ΔHpp represents peak-to-peak width. An Acquisit program was
used for data acquisition and analysis. BEAS-2B or H460 cells were mixed with
DMPO (100 mM) and PBS to a final volume of 1 ml. The mixtures were then
incubated for 5 min in a 37°C water bath. The reaction mixture was then
transferred to a flat cell for ESR measurement. Experiments were performed at
room temperature under ambient air.
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Western Blotting
After specific treatments, cells were incubated in lysis buffer containing 20 mM
Tris-HCl (pH 7.5), 1% Triton X-100, 150 mM NaCl, 10% glycerol, 1 mM Na3VO4,
50 mM NaF, 100 mM phenylmethylsulfonyl fluoride (PMSF), and protease
inhibitor mixture for 20 min on ice. After insoluble debris was precipitated by
centrifugation at 14,000 x g for 15 min at 4°C, the supernatants were collected
and assayed for protein content using bicinchoninic acid (BCA) method. Equal
amount of proteins per sample (15 µg) were resolved on 10% SDS-PAGE and
transferred onto a 0.45-µm nitrocellulose membrane. The transferred membranes
were blocked for 1 h in 5% non-fat dry milk in TBST (25 mM Tris-HCl, pH 7.4,
125 mM NaCl, 0.05% Tween 20) and incubated with the appropriate primary
antibodies and horseradish peroxidase-conjugated secondary antibodies. The
immune complexes were detected by chemiluminescence (Supersignal, West
Pico; Pierce).
Statistical Analysis
The data were expressed as means ± SD of three or more independent
experiments. Statistical analysis was performed using two-tailed and paired
Student’s t-test. P values less than 0.05 were considered statistically significant
and indicated by an asterisk
2.4 Results
Cr(VI)-Induced Cell Death
Cr(VI) induces apoptosis as the primary mode of cell death during acute
laboratory exposure (40). Dysregulation of apoptosis regulatory mechanisms is
widely accepted to be one of the hallmarks of cancer (41). To characterize the
apoptotic response to Cr(VI) treatment in our system, non-tumorigenic human
bronchial epithelial (BEAS-2B) cells and human lung cancer (H460) cells were
treated with different doses of Cr(VI) (0-50 µM) and apoptosis was determined
after 12 h by an established Hoechst 33342 assay. Figs. 1, A and B, show that
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Cr(VI) treatment caused a dose dependent increase in cell apoptosis over control
level, as indicated by increased nuclear fluorescence and chromatin
condensation of the treated cells. Notably, human lung cancer H460 cells
showed increased resistance to Cr(VI)-induced apoptosis vs. their nontumorigenic counterparts. At 20 µM Cr(VI), an approximate LD50 for BEAS-2B,
human lung cancer H460 cells exhibited approximately 10% apoptotic response.
Energy Substrate Effect on Cr(VI)-Induced Cell Death
Mitochondrial level signaling has been implicated in Cr(VI)-induced apoptosis.
Various reports suggest that mitochondria are dysregulated in cancer cells and
that cancer cells prefer to synthesize energy via less net-energy efficient
glycolysis as opposed to mitochondria-localized oxidative phosphorylation.
Accordingly, the effect of energy substrate on Cr(VI)-induced cell death was
evaluated in BEAS-2B and H460 cell populations grown in glucose containing
(G+P-) or glucose lacking, pyruvate containing (G-P+) medium. Figs. 2, A and B,
show that energy substrate modulation significantly altered Cr(VI)-induced
toxicity profile in both, BEAS-2B and H460 cells. BEAS-2B cells became
approximately 50% more sensitive to Cr(VI) 20 µM dose under energy substrate
conditions forcing oxidative phosphorylation only metabolism. Notably, cancer
H460 cells’ sensitivity increased approximately 400% when oxidative
phosphorylation was forced, resulting in approximately 8-fold increase in
apoptosis and quantitative lethal dose normalization between the two cell types
(Fig. 2C).
Effect of Cr(VI) on ROS Generation
Reactive oxygen species (ROS) have been strongly implicated in mechanism of
Cr(VI)-induced toxicity. We deployed ESR spin trapping to determine the identity
and intensity of free radical generation in Cr (VI)-stimulated BEAS-2B and H460
cells. Figs. 3A-B show the typical ESR spectra obtained from a mixture
containing 106 cells/ml, Cr(VI) and 100 mM spin trap (DMPO) in a phosphate
buffer solution (pH 7.4). The spectrum exhibits a 1:2:2:1 quartet with hyperfine
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splittings of aH = aN = 14.9 G, where aH and aN denote hyperfine splittings of βhydrogen and nitroxy nitrogen, respectively. Based on these splitting constants
(42), this quartet spectrum was assigned to DMPO/•OH adduct, which is an
indirect evidence for •OH generation. Cells alone did not generate any
observable ESR signal. The weak signal at the right side is Cr (V), which was
generated during the Cr (VI) reduction by the cells. Figure 3C shows spectral
intensity (amount of •OH radicals generated) in BEAS-2B vs. H460 cells. Notably,
non-tumorigenic BEAS-2B cells showed significantly stronger radical generation
then their cancer H460 counterparts across the 0.1–1 mM Cr(VI) range at 10 min
post-treatment. Consistent with previously observed (43) inverse relationship
between toxic stimuli initiated cellular ROS production and Δψm, we observed a
dose dependent decrease of Δψm in both cell lines (Fig. 3D) 2 h post Cr(VI)
treatment. Notably, cancer H460 cells showed approximately 50% lower Δψm as
compared to non-tumorigenic BEAS-2B cells.
Effect of Energy Substrate on Cr(VI)-Induced ROS Generation and Δψm
ROS have been demonstrated to play a critical role in Cr(VI)-induced cell death
and are detected in our system. Their origin, however, is subject to considerable
controversy. In order to determine the relative role of oxidative phosphorylation
system on radical production in our model, we utilized ESR spectroscopy to
determine qualitatively and quantitatively the effect of energy substrate on Cr(VI)induced radical production. Figs. 4A-B show 1:2:2:1 quartet with hyperfine
splittings consistent with •OH production, under conditions favoring glycolysis
and, those forcing oxidative phosphorylation, in both cell types. Notably, nontumorigenic BEAS-2B cells cultured in the medium with no glucose, showed no
significant difference in spectral intensity whereas cancer H460 cells exhibited
significantly different response to forced oxidative phosphorylation with
approximately 40% increase in spectral intensity (Fig. 4C). Both cell lines
exhibited a slight increase in Δψm in glucose lacking medium (Fig. 4D).
Effect of ROS Modulators on Cr(VI)-Induced Apoptosis

	
  

28	
  

To establish a causal relationship between the observed radical production and
apoptosis following the Cr(VI) insult, we turned to well established small molecule
inhibitors and inducers of ROS. Figs. 5A-C suggest a causal role of ROS in
Cr(VI)-induced apoptosis. Pretreatment of the cells with L-buthionine-S,Rsulfoximine (BSO), an oxidative stress inducer (44), significantly increased the
apoptotic effect of Cr(VI) in both BEAS-2B and H460 cells. Of interest, H460
apoptosis increased approximately 300% whereas BEAS-2B cells showed
significant, but relatively marginal increase of 30%. Pretreatment with N-acetylcysteine (NAC), a widely accepted, broad spectrum antioxidant, resulted in a
complete apoptosis shutdown with proportion of Hoechst 33342 positive cells
returning to control levels in both cell types.
Source of ROS Involved in Cr(VI)-Induced Apoptosis
To assess the relative importance of mitochondrial vs. cytosolic ROS on Cr(VI)induced apoptosis, cells were treated with Cr(VI) in the presence or absence of
diphenylene iodonium (DPI), a specific inhibitor of NADPH oxidase (45, 46), or
rotenone, a mitochondrial electron transport chain interrupter (47, 48), and their
effects on system apoptosis were examined. The results show that both rotenone
and DPI reduced Cr(VI)-induced apoptosis, with the effect of rotenone being
much larger (Figs. 6, A-B). These results suggest that even though cytosolic
ROS may be involved, mitochondrial oxidative phosphorylation chain seems to
generate the majority of ROS involved in Cr(VI)-induced apoptosis.
Effect of Glutathione Peroxidase and Superoxide Dismutase on Cr(VI)-Induced
Apoptosis
To confirm the role of mitochondrial ROS in Cr(VI)-induced apoptosis by means
of genetic manipulation, both cell types were stably transfected with endogenous
antioxidant enzyme GPx, MnSOD, or control plasmid, and their effects on
apoptosis were determined. GPx and MnSOD are the two primary enzymes
charged with detoxifying ROS emanating from the electron transport chain of
mitochondria and are localized in the mitochondrial matrix (49-52). Notably,

	
  

29	
  

apoptosis assay showed a significant decrease in apoptotic response to Cr(VI)
treatment in GPx- and MnSOD-transfected cells but not in mock-transfected cells
(Figs. 7A-C). These observations suggest that aside from the already established
role of hydroxyl radical (•OH), hydrogen peroxide (H2O2) and superoxide anion
(•O2‾) play critical roles in Cr(VI)-induced apoptosis.
Effect of Bcl-2 on Cr(VI)-Induced Apoptosis
To determine whether elevated mitochondrial ROS production represents a
commitment point in Cr(VI)-induced apoptosis, localized to mitochondrial matrix,
we created stable clones overexpressing Bcl-2 gene. Bcl-2 has been studied
extensively and its role in apoptosis regulation at the level of mitochondria is well
established. Specifically, it localizes to the outer mitochondrial membrane where
it inhibits a multitude of pro-apoptotic signaling events (53, 54). Mutants stably
overexpressing Bcl-2, in both cell types, showed significant reduction in Cr(VI)induced apoptosis (Figs. 8A-B). Notably, the relative intensities of apoptosis
reduction were comparable to observations in GPx and MnSOD overexpressing
clones, suggesting additional signaling cascades between mROS production and
outer mitochondrial membrane signaling events.
2.5 Discussion
In order to survive, cells must respond to changes in environment. The
adaptability of our cellular systems is considerable, but not unlimited. Nowhere is
that more evident than in neoplasia. The Warburg effect, or increased
dependency on glycolysis in cancer cells, has been a long-standing observation
(7-9). Despite numerous experimental findings of this metabolic alteration in a
wide spectrum of human cancers, the mechanisms underlying it and potential
therapeutic implications still remain a subject of considerable controversy (8-10).
The central question is whether a shift to glycolysis is simply an adaptation due
to low availability of oxygen in tumor microenvironment (Figure 9, a majority
opinion), or, a consequence of ‘‘respiratory system injury’’, as Warburg himself
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thought, forcing the cells to use the glycolytic pathway to generate ATP. While
multiple lines of evidence in the literature support both contentions, several
fundamental challenges face “the majority opinion”. First, cancer cells maintain
the glycolytic phenotype in cell culture where oxygen is freely available. Second,
the contention that once adaptation to glycolysis occurs, it becomes irreversible,
is not supported by evidence. Contrary, several reports highlight significant
plasticity of mitochondria under changing metabolic conditions (11-13). If
mitochondria are so energy substrate versatile, and produce 36 ATP molecules
per glucose unit vs. 2 ATPs from glycolysis, what benefit would outweigh the
tremendous net energy cost? Collectively, our data point toward ROS (Figure
10).
Cr(VI) is a known human carcinogen that has been associated with lung cancer
(25). Its cytotoxic and mutagenic effects have been studied extensively and point
toward ROS as causal in Cr(VI)-induced toxicity and mutagenesis. Indeed, our
data show a dose dependent increase in apoptosis in non-tumorigenic BEAS-2B
cells as well as tumorigenic H460 cells. H460 cells, however, are approximately 4
fold more resistant to Cr(VI)-induced apoptosis than their non-tumorigenic
counterparts (Figs. 1A-B). When exposed to a functioning oxidative
phosphorylation-dependent, energy substrate-only, environment, the observed
apoptosis resistance is abrogated (Figs. 2A-C). This is the first report of energy
substrate modulation of Cr(VI)-induced toxicity indicating a link between oxidative
phosphorylation only metabolism and mechanism of Cr(VI)-induced toxicity.
Furthermore, observations in Fig. 2 suggest critical ‘differences’ between H460
and BEAS-2B cells in support of Warburg’s “respiratory defect”. Given the
observations in Figure 2, we focused on delineating deeper mechanistic aspects
of Cr(VI)-induced apoptosis in our system.
Cr(VI) is actively transported into cells by anionic transport system at the cellular
level (55) and is metabolically converted to the ultimate reduced form, Cr(III), in a
process that also produced ROS. Since generation of ROS is a consequence of
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Cr(VI) exposure, we also demonstrated the role of ROS in Cr(VI)-induced
apoptosis of non-tumorigenic BEAS-2B and tumorigenic H460 cells. Consistent
with the observation that reduction of Cr(VI) inside the cell produces ROS, our
results showed that Cr(VI) was able to induce •OH radical generation in both cell
types (Figs. 3A-B). The relative intensity of the ESR spectra was significantly
lower in the tumorigenic H460 cells (Fig. 3C) at both concentrations studied.
Decrease in mitochondrial membrane potential has been linked to mitochondrial
ROS production in response to toxic stimuli (11, 13) as well as overall
mitochondrial function (15). This was the case in our system as well where we
observed a dose dependent decrease in mitochondrial membrane potential in
both cell types (Fig. 3D). The relative decrease was significantly higher in nontumorigenic BEAS-2B cells.
In order to establish the link between Cr(VI)-induced ROS production and
functioning mitochondrial metabolism, we evaluated the relative ESR peak
intensity as a function of energy substrate available to the cells. Figures 4A-C
show that conditions forcing oxidative phosphorylation resulted in a significant
increase in ROS production in tumorigenic H460 cells, whereas BEAS-2B cells
showed no significant difference. Consistent with the observed energy substrate
effects on ROS production, we observed a significant increase in the
mitochondrial membrane potential in both cell types (Fig. 4D) when oxidative
phosphorylation was forced. Since we observed the correlation between energy
substrate, apoptosis and ROS production, we set out to establish the potential
causal relationship between the observed Cr(VI)-induced ROS and apoptosis.
Increase in ROS production was achieved via pretreatment of the cells with an
established ROS inducer BSO, while NAC was used as a ROS inhibitor. BSO
pretreatment led to a significant increase in Cr(VI)-induced apoptosis in both cell
types, while NAC virtually abrogated the effect (Figs. 5A-C), suggesting a causal
relationship between the ROS and apoptosis in our system. This observation was
consistent with previous reports on the role of ROS in Cr(VI)-induced apoptosis
(29-31).
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While ROS production is a known factor in Cr(VI)-induced toxicity, their subcellular origins are not well understood. To determine the source of ROS involved
in Cr(VI)-induced apoptosis in our system, we utilized DPI and rotenone.
Rotenone has previously been shown to inhibit mitochondrial ROS while DPI is
known to inhibit cellular NADPH oxidase; both are considered as indicators of the
mitochondrial and cytosolic ROS, respectively (56-58). Cr(VI)-induced ROS
generation and apoptosis was significantly inhibited by DPI and rotenone, with
the effect of the latter being more dominant (Fig. 6A-B) in both cell types. This
indicates that total ROS produced are important in Cr(VI)-induced apoptosis, but
mitochondrial ROS play a major role in our system. DPI and rotenone are widely
used in mechanistic studies; however, secondary effects cannot be excluded due
to their small-molecule nature. In order to confirm the causal relationship
mitochondrial ROS plays in Cr(VI)-induced apoptosis in our system, stable cell
lines overexpressing GPx and MnSOD were created for both cell types. Gene
transfection studies using GPx- and SOD-overexpressing cells confirmed that
mitochondrial ROS play a crucial role in Cr(VI)-induced apoptosis (Figs. 7A-C).
Apoptosis was virtually abrogated in both, the tumorigenic H460 as well as nontumorigenic BEAS-2B mutants.
To determine whether mROS production in our system represents a point of no
return for the cell in Cr(VI)-induced apoptosis, stable clones overexpressing Bcl-2
gene were created. Bcl-2 has been studied extensively and its role in apoptosis
regulation at the level of mitochondria is well established. Specifically, it localizes
to the outer mitochondrial membrane where it inhibits a multitude of pro-apoptotic
signaling events (53, 54). Mutants stably overexpressing Bcl-2, in both cell types,
showed significant reduction in Cr(VI)-induced apoptosis (Figs. 8A-B)
comparable in intensity to the observations in GPx and MnSOD-overexpressing
clones. Together, these observations suggest additional signaling cascades
between mROS production in the matrix and outer mitochondrial membrane
signaling events.
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In summary, our data provide evidence that apoptosis induced by Cr(VI) is
mediated through the mitochondria-dependent signaling pathway. ROS play a
causal role in Cr(VI)-induced apoptosis of non-tumorigenic human bronchial
epithelial BEAS-2B cells and human lung cancer H460 cells. The mechanism by
which Cr(VI) induces apoptosis involves rapid generation of ROS in the
mitochondrial matrix and consequent depolarization of the outer mitochondrial
membrane. Further, mitochondrial ROS generation resulting from Cr(VI) insult is
quantitatively dependent on the degree of cellular commitment to oxidative
phosphorylation driven energy production. Forcing of oxidative phosphorylationonly metabolism leads to an abrogation of native apoptosis resistance in human
lung cancer H460 cells vs. their non-tumorigenic BEAS-2B counterparts.
Collectively, our data present a mechanistic advancement in the understanding
of molecular effectors underlying the Warburg’s “respiratory defect” hypothesis
and put mitochondrial ROS as causal agents of programmed cell death in Cr(VI)induced toxicity and carcinogenesis (Fig. 11).
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FIGURE 1. Induction of apoptosis by Cr(VI) in human lung epithelial BEAS-2B and human
lung cancer H460 cells. A, subconfluent monolayers of BEAS-2B and H460 cells were exposed
to varying doses of Cr(VI) (0-50 µM) for 12 h, and the cells were analyzed for apoptosis by
Hoechst 33342 assay. B, fluorescence micrographs of treated cells stained with Hoechst dye.
Apoptotic cells exhibited shrunken and fragmented nuclei with bright nuclear fluorescence.
Values are mean ± S.D. (n > 3). *, p < 0.05 versus non-treated control.
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FIGURE 2. Effect of energy substrate on Cr(VI)-induced apoptosis in human lung epithelial
BEAS-2B and human lung cancer H460 cells. A, subconfluent monolayers of BEAS-2B were
exposed to 20 µM dose of Cr(VI) for 12 h in either G+P- or G-P+ medium, and the cells were
analyzed for apoptosis by Hoechst 33342 assay. B, subconfluent monolayers of H460 cells were
exposed to 20 µM dose of Cr(VI) for 12 h in either G+P- or G-P+ medium, and the cells were
analyzed for apoptosis by Hoechst 33342 assay. C, Relative apoptosis resistance in H460 vs.
BEAS-2B cells as a function of available energy substrate. Values are mean ± S.D. (n > 3). *, p <
0.05 versus non-treated control.
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FIGURE 3. Cr(VI)-induced ROS production and mitochondrial membrane depolarization. A,
BEAS-2B cells were exposed to varying concentrations of Cr(VI) (0.1 and 1 mM) and the cells
were analyzed for ROS production using electron spin resonance (ESR) spectroscopy. B, H460
cells were exposed to varying doses of Cr(VI) (0.1 and 1mM) and the cells were analyzed for
ROS production using ESR. C, Relative difference in the ROS intensity in BEAS-2B and H460
cells. D, Mitochondrial membrane depolarization as indicated by JC-1 fluorescence. Values are
mean ± S.D. (n > 3). *, p < 0.05 versus non-treated control.
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FIGURE 4. Effect of energy substrate on ROS production and mitochondrial membrane
depolarization. A, BEAS-2B cells were exposed to 1 mM Cr(VI) and the cells were analyzed for
ROS production using electron spin resonance spectroscopy (ESR) in G+P- and G-P+ media. B,
H460 cells were exposed to 1 mM Cr(VI) and the cells were analyzed for ROS production using
electron spin resonance spectroscopy (ESR) in G+P- and G-P+ media. C, Relative difference in
the ROS intensity in BEAS-2B and H460 cells as a function of energy substrate. D, Relative
difference in mitochondrial membrane depolarization as a function of energy substrate. Values
are mean ± S.D. (n > 3). *, p < 0.05 versus BEAS-2B cells.
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FIGURE 5. Effect of ROS modulators on Cr(VI)-induced apoptosis in BEAS-2B and H460
cells. A, subconfluent monolayers of BEAS-2B cells were pretreated for 1 h with BSO or NAC
and exposed to 20 µM Cr(VI) for 12 h, and the cells were analyzed for apoptosis by Hoechst
33342 assay. B, subconfluent monolayers of H460 cells were pretreated for 1 h with BSO or NAC
and exposed to 20 µM Cr(VI) for 12 h, and the cells were analyzed for apoptosis by Hoechst
33342 assay. C, fluorescence micrographs of treated cells stained with Hoechst dye. Apoptotic
cells exhibited shrunken and fragmented nuclei with bright nuclear fluorescence. Values are
mean ± S.D. (n > 3). *, p < 0.05 versus non-treated control. ** versus Cr(VI)-treated control.
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FIGURE 6. Source of ROS involved in Cr(VI)-Induced Apoptosis A, subconfluent
monolayers of BEAS-2B cells were pretreated for 1 h with ROT or DPI and exposed to 20 µM
Cr(VI) for 12 h, and the cells were analyzed for apoptosis by Hoechst 33342 assay. B,
subconfluent monolayers of H460 cells were pretreated for 1 h with ROT or DPI and exposed to
20 µM Cr(VI) for 12 h, and the cells were analyzed for apoptosis by Hoechst 33342 assay. Values
are mean ± S.D. (n > 3). *, p < 0.05 versus non-treated control. ** versus Cr(VI)-treated control.
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FIGURE 7. GPx and MnSOD overexpression increases cell death resistance to Cr(VI). A,
Western blot analysis. BEAS-2B and H460 cells were transfected with GPx, MnSOD, or control
pcDNA3 plasmid. β-actin was used as a loading control. B and C, Transfected cells were treated
with 20 µM Cr(VI) for 12 h and the effect of GPx and MnSOD overexpression on apoptosis was
determined by Hoechst 33342 assay. Plots are mean ± S.D. (n = 3). *, p < 0.05 versus mocktransfected Cr(VI)-treated controls.
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FIGURE 8. Bcl-2 overexpression decreases Cr(VI)-induced apoptosis. A, Western blot
analysis. BEAS-2B and H460 cells were stably transfected with myc-tagged Bcl-2 plasmid or
control pcDNA3 plasmid. β-actin was used as a loading control. B, Transfected cells were treated
with 20 and 50 µM Cr(VI) for 12 h and apoptosis was determined by Hoechst 33342 assay. Plots
are mean ± S.D. (n = 3). *, p < 0.05 versus mock-transfected controls.
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Figure 9. Prevailing model of carcinogenesis. Normal epithelial cells (grey) become
hyperproliferative (pink) following induction. As they reach the oxygen diffusion limit, they become
hypoxic (blue), which can either lead to cell death (apoptotic cells shown with blebbing) or
adaptation of a glycolytic phenotype (green), which allows cells to survive. As a consequence of
glycolysis, lesions become acidotic, which selects for motile cells (yellow) that eventually breach
the basement membrane.
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Figure 10. Mitochondrial ROS production and defense. Superoxide (O2 ) generated by the
respiratory chain is mostly released to the matrix at complex I and the inter membrane space
.(IMS) at complex III. O2 can naturally dismute to hydrogen peroxide (H2O2) or is enzymatically
dismuted by matrix MnSOD (1) or Cu/ZnSOD (2) in the IMS or cytosol. H2O2 is detoxified in the
matrix by catalase (3), the thioredoxin/thioredoxin peroxidase system (4), or the
glutathione/glutathione peroxidase system (5). Alternately, H2O2 can react with metal ions to
.
.generate the highly reactive hydroxyl radical ( OH) via Fenton chemistry (6). O2 is not membrane
permeable but can pass through ion channels (solid lines), whereas H2O2 can pass freely through
.membranes (dashed lines). Bcl-2 modulates MPTP opening as well as VDAC activity. O2 ,
superoxide; H2O2, hydrogen peroxide; MnSOD, manganese superoxide dismutase; Cu/ZnSOD,
copper/zinc superoxide dismutase; CAT, catalase; THD, NADH transhydrogenase; TR,
red
ox
thioredoxin reductase; TPx, thioredoxin peroxidase; TRx , reduced thioredoxin; TRx , oxidized
thioredoxin; GSH, glutathione; GSSG, glutathione disulfide; IMAC, inner membrane ion channel;
VDAC, voltage dependant anion channel; MPTP, mitochondrial permeability transition pore; Bcl2, B-cell lymphoma 2 antiapoptotic effector.
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Figure 11. Proposed mechanism contributing to Cr(VI)-induced toxicity and carcinogenesis
Cr(VI) accumulates in the mitochondrial matrix at higher relative concentrations than in the
cytosol/nucleus and it significantly amplifies the ROS burden via Fenton chemistry “explosion”
leading to acute and chronic (mDNA damage) “respiratory defect”. Consequently, mitochondrial
signaling integrity is lost and the cell (1) amplifies glycolysis as the only remaining viable energy
source and (2) loses commitment phase apoptotic signaling hub.
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CHAPTER III
Malignant Transformation and Tumorigenesis of Chromium (VI)Exposed Lung Cells and their Inhibition by Bcl-2 Knockdown
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3.1 Abstract
Environmental exposure to heavy metals such as hexavalent chromium (Cr(VI))
is associated with an increased incidence of human lung cancer. Elucidation of
phenotypic changes, specific molecular effectors and their hierarchy in Cr(VI)induced carcinogenesis has been limited due to the lack of appropriate
experimental models especially for long-term exposure studies. We have
developed an in vitro-in vivo chronic exposure model for mechanistic studies of
Cr(VI)-induced carcinogenesis which is applicable to other xeno-carcinogenesis
studies. Long-term exposure to Cr(VI) leads to malignant transformation of
human lung epithelial BEAS-2B cells, as indicated by their increased cell
migration, invasion, proliferation, and colony formation activities. Cr(VI)transformed cells induced tumorigenesis in nude mice comparable to that of well
established human lung cancer H460 cells, whereas passage-matched control
BEAS-2B cells showed no tumor development. To provide a mechanistic insight
to the tumorigenic process, stable knockdown mutants of Cr(VI)-transformed
cells and H460 cells exhibiting downregulated Bcl-2 phenotype were generated
and evaluated for tumor associated properties in vitro and in vivo. The Bcl-2
knockdown mutants showed a substantial decrease in the rates of colony
formation, invasion, migration and proliferation, as well as tumor formation in
mice, in comparison to vector controls. These results indicate a novel role of Bcl2, beyond apoptosis regulation, to be a key regulator of malignant transformation
and tumorigenesis in vivo. The model described here may provide utility to other
xeno-carcinogenesis studies, including those of heavy metals which currently
lack effective in vivo tumor development experimental means.
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3.2 Introduction
Lung cancer is the leading cause of cancer mortality worldwide and yet the
etiology of lung cancer is poorly understood. Current research indicates that
long-term exposure to inhaled carcinogens has the greatest impact on the risk of
lung cancer. Cr(VI) compounds are ubiquitous carcinogens associated with the
incidence of lung cancer in humans. Several epidemiological studies in the last
few decades have associated exposure to Cr(VI) with the induction of lung
cancer in workers in various occupational settings (1-5). Cr(VI) compounds are
also present in cigarette smoke, automobile emissions, and are widespread in
the environment, e.g., Cr(VI)-contaminated water. In the United States, an air
quality survey indicated that people in several residential areas are exposed to
particulate airborne chromium at concentrations exceeding 100 times the chronic
toxicity benchmark (6). Therefore, in addition to occupational exposure,
environmental chromium is an emerging concern for its associated long-term
carcinogenic effect of the lungs.
Although several epidemiological studies have demonstrated the carcinogenic
effect of Cr(VI) compounds, animal studies have yielded negative or inconsistent
results (7-9) due to genetic variations or other predisposing factors that are not
clearly understood. The lack of appropriate animal models has hindered the
efforts to identify the mechanisms of Cr(VI)-induced carcinogenesis; therefore,
even though Cr(VI) compounds have been identified as human carcinogens (10),
the underlying mechanisms remain poorly understood. To date, most Cr(VI)
carcinogenesis studies have focused on short-term or acute effects; however,
carcinogenesis is a multi-step process requiring long-term exposure to the
carcinogen. To mimic the pathologic exposure condition, we developed an in
vitro chronic exposure model combined with in vivo tumorigenesis model to aid
mechanistic studies of Cr(VI)-induced lung carcinogenesis. Using the combined
model, we also investigated the potential role of Bcl-2 in the carcinogenic
process.
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Bcl-2 is a key apoptosis-regulatory protein known to be important in the
regulation of Cr(VI)-induced apoptosis (11). Chronic exposure of lung epithelial
cells to Cr(VI) led to apoptosis resistance and upregulation of Bcl-2 (12). Several
apoptosis-resistant lung cell lines and tumor specimens have also been shown to
overexpress Bcl-2 (13-15). This protein has also been shown to be upregulated
in many forms of cancer, including 90% of colorectal cancer, 70% of breast
cancer, and 30-60% of prostate cancer (16, 17). While these studies suggest the
possible role of Bcl-2 in Cr(VI)-induced carcinogenesis, direct evidence for its
role is lacking. In this study, we used a molecular approach to knockdown Bcl-2
and measured its effects on malignant transformation and tumorigenic properties
of human lung epithelial cells chronically exposed to Cr(VI). We also used
bioinformatics approach to aid the mechanistic investigations of Bcl-2’s role in
Cr(VI)-induced carcinogenesis.
3.3 Materials and Methods
Chemicals and Reagents
Sodium dichromate (Na2Cr2O7.2H2O) [Cr(VI)] was obtained from Sigma (St.
Louis, MO). Hoechst 33342 were obtained from Molecular Probes (Eugene,
OR). Lipofectamine was from InVitrogen (Carlsbad, CA). Antibodies for Bcl-2, βactin, and peroxidase-conjugated secondary antibodies were from Santa Cruz
Biotechnology (Santa Cruz, CA).
Cell Culture
Human lung epithelial BEAS-2B cells and human lung cancer epithelial H460
cells were obtained from American Type Culture Collection (Manassas, VA).
BEAS-2B cells were cultured in Dulbecco’s modified eagle medium containing
5% fetal bovine serum (FBS), 2 mM L-glutamine, 100 units/ml penicillin and
streptomycin. H460 cells were cultured in RPMI 1640 medium containing 10%
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FBS, 2 mM L-glutamine, 100 units/ml penicillin and streptomycin in a 5% CO2
environment at 37ºC.
Chronic Cr(VI) Exposure
BEAS-2B cells were continuously exposed to 5 µM Cr(VI) in culture in 5% CO2 at
37ºC. The cells were passaged weekly at preconfluent densities using a solution
containing 0.05% trypsin and 0.5 mM EDTA. Cr(VI)-exposed BEAS-2B cells are
designated as BEAS-Cr cells so as to distinguish them from the parental BEAS2B cells. Parallel cultures grown in Cr(VI)-free medium provided passagematched controls. After 24 weeks of exposure, Cr(VI)-exposed cells were
cultured in normal medium and their tumorigenic potential was assessed by
various measurements below.
Cell Growth Assay
Cells (1x105 cells) were seeded on 60-mm cell culture dishes and were
incubated at 37oC in a 5% CO2 incubator. At specific times after the incubation,
cells were trypsinized and analyzed for cell number using Countess® automated
cell counter (InVitrogen, Carlsbad, CA).
Soft Agar Colony Formation Assay
Soft agar assay was performed as previously described with minor modifications
(18). The cell lines studied (3×104 cells) were mixed with tissue culture medium
containing 0.5% agar to result in a final agar concentration of 0.33%. Cell
suspension (1.5 ml) was plated in 60-mm dishes coated with 7 ml of 0.5% agar in
tissue culture medium. After 2 weeks, the average number of colonies with a
diameter of more than 50 cells was scored under a light microscope.
Invasion Assay
Invasion assays were performed using Transwell invasion chambers coated with
Matrigel (50 µl per filter) (BD, USA) according to the manufacturer’s protocol.
Cells were cultured for 48 h and transferred on the top of Matrigel-coated
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invasion chambers in a serum-free medium (1x105 cells per Transwell). Medium
containing 5% FBS was added to the lower chambers. After incubation for 24 h,
cells that remained on the top of the filter were scrubbed off and cells that
migrated to the lower surface were fixed in 90% alcohol and followed by a crystal
violet stain.
Migration Assay
Cell migration was determined by wound assay. Cells were cultured in 24-well
plate and then a wound space was made with 1 mm width tip. Cells were
incubated under standard conditions for 24 h, after which they were washed and
examined under a light microscope. Analysis of cell migration was performed by
using an average wound space from ten random fields of view, and the
percentage of change in the wound space was calculated using the formula: %
change = (average space at time 0 h) - (average space at time 24 h) / (average
space at time 0 h) x 100. Relative cell migration was calculated by dividing the
percentage change in the wound space of indicated cells by that of the control
cells in each experiment.
Generation of Bcl-2 Knockdown Clones
Lentiviral transduction particles carrying short hairpin RNA (shRNA) sequence
against human Bcl-2 (5’-CCGGGTGATGAAGTACATCCATTATCTCGAGATAAT
GGATGTACTTCATCACTTTTG-3’) and control non-target sequence (5’-CCGGC
AACAAGATGAAGAGCACCAACTCGAGTTGGTGCTCTTCATCTTGTTGTTTTT3’) were used to knockdown Bcl-2 expression in BEAS-Cr and H460 cells. The
viral vectors were obtained from Sigma (Cat # SHVRS-NM_000633 and
SHC002V, respectively) and were used according to the manufacturer’s protocol.
Briefly, the cells were seeded in 6-well plates (5x105/well) and incubated with
Bcl-2 shRNA lentiviral particles or control particles at the multiplicity of infection
(MOI) of 1.5 in the presence of hexadimethrine bromide (8 µg/ml) for 36 h. For
generation of stable clones, cells were plated onto 10-cm dishes and cultured for
14 d with puromycin (1 µg/ml). Resistant clones expressing varying levels of Bcl-
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2 were isolated using cloning cylinders (Bellco Glass, Vineland, NJ) and
transferred for expansion and analysis by Western blotting.
Western Blotting
Cells were incubated in a lysis buffer for 20 min on ice. After centrifugation at
14,000g for 15 min at 4oC, cell supernatants were collected and assayed for
protein content. Equal amounts of protein per sample (15 µg) were resolved on
10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred
onto 0.45-µm nitrocellulose membranes. The transferred membranes were
blocked for 1 h in 5% non-fat dry milk in TBST (25 mM Tris-HCl, pH 7.4, 125 mM
NaCl, 0.05% Tween-20) and incubated with appropriate primary antibodies,
followed by horseradish peroxidase-conjugated secondary antibodies. The
immune complexes were detected by chemiluminescence (Supersignal® West
Pico, Pierce Biotechnology, Rockford, IL) and quantified by imaging densitometry
using UN-SCAN-IT automated digitizing software (Silk Scientific, Orem, UT).
Mean densitometry data from independent experiments were normalized to the
control.
In Vivo Tumor Xenograft Model
Athymic (nu/nu) male nude mice, obtained from Jackson Laboratory (Bar Harbor,
ME), were housed under pathogen-free conditions and fed autoclaved diet and
water ad libitum. To establish tumor xenografts in mice, BEAS-2B, BEAS-Cr,
H460 and Bcl-2 knockdown cells (1x106 cells) were suspended in 1:1 medium
mixed with Matrigel and were injected subcutaneously on the left and right flanks
of each mouse. Tumor size was measured at 14 d post-injection by using a
caliper, and the tumor volume was determined using the formula: 0.5238 x L
(length) x W (width) x H (height) of the tumor. All procedures were conducted in
accordance with the guidelines for the Use and Care of Laboratory Animals and
approved by the Institutional animal care and use committee.
Bcl-2 Interactome Analysis
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The Ingenuity Pathways Analysis (IPA) software (Ingenuity Systems, Redwood
City, CA) was used to analyze currently published Bcl-2 interactome. The
Ingenuity database is the largest curated database of previously published
findings on mammalian biology from the public literature (i.e., MEDLINE).
Reports on individual studies of genes in human, mouse or rat were first
identified from peer-reviewed publications, and findings were then encoded into
ontology by content and modeling experts. Network analysis using the
knowledge base was used to further identify direct interactions between
mammalian orthologues. The Bcl-2-interactome is a graphical representation of
its published molecular relationships. Molecules are represented as nodes, and
the biological relationship between two nodes is represented as an edge (line).
Nodes are displayed using various shapes that represent the functional class of
the gene product. Edges are displayed with various labels that describe the
nature of the relationship between the nodes.
Statistical Analysis
The data were expressed as means ± SD of three or more independent
experiments. Statistical analysis was performed using two-tailed and paired
Student’s t-test. P values less than 0.05 were considered statistically significant
and indicated by an asterisk.
3.4 Results
Cell Growth and Colony Formation
BEAS-2B cells were continuously exposed to Cr(VI) for 24 weeks in culture as
described in Materials and Methods. In order to assess the relative tumorigenic
potential of the exposed cells (BEAS-Cr), we compared their growth and colony
formation characteristics to those of the passage-matched BEAS-2B cells serving
as a negative control, and human lung carcinoma H460 cells serving as a
positive control. The BEAS-2B cell line has been used previously to study the
carcinogenic potential or effects of various chemicals and biological agents (19-
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21). The H460 cell line has been evaluated extensively in mechanistic studies of
human lung cancer. Statistically significant increase in growth capacities was
observed as early as 48 h in BEAS-Cr and H460 cells as compared to control
BEAS-2B cells (Figures 1A-B). By 96 h, the growth rates of BEAS-Cr and H460
cells were more than double that of the control BEAS-2B cells. Next, soft agar
colony formation assay was performed to assess relative colony formation
capacities. BEAS-2B, BEAS-Cr, and H460 cells were subjected to colony
formation assay by growing them on agar plates so as to assess anchorageindependent growth. After 2 weeks, significant colony formation was observed in
BEAS-Cr cells with a 7-fold increase as compared to passage-control BEAS-2B
cells which also formed very few, slow growing colonies (Figures 1C-D). The
H460 human lung cancer cells exhibited the highest colony formation capacity,
out-growing the BEAS-2B cells by approximately 8-fold and BEAS-Cr cells by
approximately 1.5-fold.
Migration and Invasion
We next investigated the relative, aggressive-malignant phenotype, capacities
using the same comparative approach. The H460 cells showed the highest
invasion capacity with BEAS-Cr cells invading at the rate of 70% relative to
H460, and BEAS-2B invading at 15% (Figures 2A-B). A 7-fold increase in
invasion rate was observed in BEAS-Cr as compared to BEAS-2B cells. The
highest migration capacity was observed in H460 cells followed by BEAS-Cr
cells, at approximately 75% of H460 cells, and finally, BEAS-2B cells, at less
than 10% of H460 cells (Figures 2C-D). Together, these studies indicate that
chronic exposure of non-tumorigenic BEAS-2B cells induced malignant
transformation of the cells showing phenotypic characteristics similar to those of
the tumorigenic H460 cells.
Bcl-2 Expression and Sensitivity to Cr(VI)
Apoptosis is the primary mode of cell death following an insult with Cr(VI) at
physiologically relevant doses (11, 22). Apoptosis resistance, on the other hand,
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is the central objective of “one renegade cell” on its quest toward malignancy.
Previous studies have shown that Bcl-2 is a key protein involved in apoptosis
resistance to Cr(VI) (11, 12). Whether this is a mechanistic feature unique to
specific cell systems or a more general feature of carcinogenesis is uncertain.
To test this possibility, we evaluated endogenous Bcl-2 protein expression across
our 3 cell type comparative system using Western blots. The results show that
BEAS-Cr cells exhibited a substantial higher amount of Bcl-2 relative to that of
passage-control BEAS-2B cells, but comparable to that of H460 cells (Figure
3A). In response to acute Cr(VI) treatment, Bcl-2 protein expression was
substantially downregulated in BEAS-2B cells, and to a much lesser extent in
BEAS-Cr and H460 cells (Figure 3B), suggesting a mechanistic similarity
between the latter two cell types.
Bcl-2 Knockdown Effect in Vitro
Mutant cell lines exhibiting stably downregulated Bcl-2 were generated using
RNA interference and clonal selection. Maximum Bcl-2 downregulation in BEASCr mutants (85%) was achieved in clone 2, which was used for the remainder of
the study (Figure 4A). H460 clone 1 showed 75% Bcl-2 reduction and was used
for further study. Scramble sequences were used to generate appropriate
controls for the BEAS-Cr and H460 mutant cells. Downregulation of Bcl-2
reduced proliferation rates of both BEAS-Cr and H460 cells by about 50% at 96 h
(Figure 4B). Next, the effect of Bcl-2 knockdown on colony formation capacity
was evaluated. The BEAS-Cr mutant exhibited approximately 60% reduction in
colony formation while a 40% reduction was observed in the H460 mutant as
compared to their respective controls (Figure 4C). The trend continued when
migration and invasion capacities were assessed with both mutants showing
significant decrease in these tumor-associated properties compared to controls
(Figures 4D-E).
Bcl-2 Knockdown Effect In Vivo
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To assess the potential tumorigenicity of Cr(VI)-transformed BEAS-Cr cells and
role of Bcl-2 in the tumorigenic process, experiments were performed using a
xenograft mouse model. The cells and their knockdown mutants were
subcutaneously injected into nude mice. At one week after the injection, small
tumors were formed at the injection site in mice receiving BEAS-Cr and H460
cells, whereas mice receiving BEAS-2B cells did not develop tumors. At 14 days
post-injection, large tumors were found in the BEAS-Cr (Figure 5A) and H460
(Figure 5B) mice, whereas no or very small lumps were observed in the BEAS2B control mice. To our knowledge, this is the first demonstration of in vivo
tumorigenesis with Cr(VI)-transformed cells. Mice receiving Bcl-2 knockdown
mutants, either BEAS-Cr or H460, showed a substantial reduction in tumor
volume as compared to their respective controls (Figures 5A-B). These results
indicate the role of Bcl-2 in tumorigenesis of Cr(VI)-transformed cells. The
inhibition of tumor growth in H460 mutant mice also implicates the general role of
Bcl-2 in tumorigenesis of lung cancer cells.
Bcl-2 Interactome Analysis
In order to establish a strategy towards a better understanding of the
mechanism(s) involved in Bcl-2’s contribution to carcinogenesis, we performed
an extensive PubMed database search for possible molecular targets. The initial
query for Bcl-2 returned 33,970 hits! We realized that other approaches may
need to be evaluated given the complexity of Bcl-2 cellular role(s). Following the
analysis of available options, we turned to Ingenuity Pathways Analysis (IPA).
IPA integrates the primary literature into easily searched and visualized networks
allowing for orders of magnitude faster evaluation of cellular signaling cascades.
Figure 6A shows the initial IPA query of Bcl-2’s interactions reported to date (IPA
v8.6). 741 molecules have thus far been reported to interact with Bcl-2 either
directly or indirectly. In order to make the network more relevant to our model,
we filtered for only those interactions reported in humans (Figure 6B). This
reduced the interaction network to 56 molecules organized by cellular localization
(Bcl-2-interactome). Given that we selectively targeted Bcl-2 and observed
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significant consequences on tumor-associated properties, we asked IPA to map
only the downstream components of human Bcl-2-interactome (Figure 6C). The
query returned 20 molecules. As we progressed from Figure 6A overwhelming
complexity to Figure 6C, the current mechanistic evidence of Bcl-2’s role in
carcinogenesis emerged, as did a new approach to scientific query.
3.5 Discussion
Although Cr(VI) has been identified as a potent human carcinogen, the
mechanism underlying the carcinogenic process remains unclear due in part to
the lack of appropriate experimental models for long-term exposure studies. In
this study, we reported a combined in vitro-in vivo model for Cr(VI)
carcinogenesis studies using chronically exposed bronchial epithelial BEAS-2B
cells and a mouse tumorigenesis model. Bronchial epithelial cells were chosen
in this study because they are a key target for Cr(VI)-induced carcinogenesis.
BEAS-2B cells have been widely used in the literature to define conditions under
which various agents and oncogenes cause neoplastic transformation (19-21).
Inclusion of the passage-control BEAS-2B cells and bronchial carcinoma H460
cells into direct comparisons was critical when assessing the significance of
tumorigenic properties in the evolved BEAS-Cr phenotype. H460 cells are a well
established model for in vitro and in vivo mechanistic studies of lung
carcinogenesis and therefore represent a positive control. For BEAS-Cr cells,
significant growth increase was observed as early as 48 h and at 96 h the growth
rate was double that of control BEAS-2B cells (Figures 1A-B). H460 cells
proliferated even faster, at approximately 2.5 times that of BEAS-2B cells. This
could be in part due to 10% serum content of standard culture medium for H460
cells vs. 5% for BEAS-2B and BEAS-Cr cells. We performed a series of direct
comparisons with all cell lines cultured at 5% serum and observed a slight
decrease in H460 cell growth (data not shown), however we opted to continue at
10% since it is the literature standard.
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Anchorage-dependent growth is a typical feature of normal cells and controls cell
division (23), however when cells are transformed they lose this property.
Anchorage-independent growth has been widely correlated with tumorigenicity
and invasiveness in several cancer cell types (23). Soft agar assay is a stringent
test to study the ability of cells to undergo anchorage-independent growth. The
number of colonies formed by BEAS-Cr cells was about 7 times more than that in
control BEAS-2B cells, confirming the carcinogenic potential of Cr(VI)transformed cells (Figures 1C-D). H460 cells formed colonies at even higher
rate, exceeding BEAS-Cr cells by about 30%. Interestingly, bronchial epithelial
BEAS-2B cells obtained at autopsy of non-cancerous individuals also formed a
small number of slow growing colonies on soft agar. This could be due to the
fact that BEAS-2B cells are reported to possess mutated and dysfunctional p53
tumor suppressor gene (19, 24). Additionally, the American Type Culture
Collection (ATCC) indicates that the BEAS-2B cell line forms colonies in
semisolid medium but is non-tumorigenic in immunosuppressed mice.
Therefore, the colony formation observed in BEAS-2B cells is due to the
indigenous properties of the cell and not because of their tumorigenic potential.
Cr(VI)-transformed cells were further characterized for their invasive and
migratory properties and compared to those of established lung cancer H460
cells. Invasion and migration were shown to increase significantly as compared
to passage-control BEAS-2B cells (Figures 2A-B). Recent reports indicate that
BEAS-2B are non-tumorigenic, aneuploid cells but can undergo squamous
differentiation in response to serum and transforming growth factor-β (25).
However, since passage-control BEAS-2B cells showed no phenotypic changes
or malignant behavior, it can be concluded that BEAS-Cr cells are Cr(VI)transformed BEAS-2B cells and not BEAS-2B cells that have undergone
differentiation and show altered phenotype due to continued passaging.
Carcinogenesis is a multistep process involving progressive transformation of
normal cells into malignant phenotypes along with the aberrant accumulation of
such abnormal cells (26, 27). Cr(VI) may affect the carcinogenic process during
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malignant transformation, i.e., by causing DNA mutation and damage, or
aberrant cell accumulation, i.e., through evasion of apoptosis. Sensitivity to
apoptosis depends on the expression level of various apoptosis-regulatory
proteins. A functional loss of pro-apoptotic proteins and/or increased expression
of anti-apoptotic proteins can confer resistance to apoptotic stimuli (28, 29). Bcl2 is a key anti-apoptotic protein involved in the apoptosis resistance to Cr(VI)
(11). A lesser known function of Bcl-2 is its tumorigenic properties. Bcl-2
expression has been reported to be elevated in many forms of cancer (13-17)
and was found in this study to be upregulated in Cr(VI)-transformed BEAS-Cr
cells (Figure 3A). In order to evaluate the potential relationship between Bcl-2
and tumorigenic properties, gene knockdown experiments were performed to
allow direct assessment of the Bcl-2’s contribution to tumorigenic phenotype of
BEAS-Cr and H460 cells. Our results show that Bcl-2 knockdown leads to
significant reduction of all tumorigenic properties evaluated (Figures 4A-E).
While Bcl-2 is a well established oncogene, its ‘oncogene’ status is largely
attributed to the evolution of chemoresistance via modulation of cell’s apoptotic
machinery. To the best of our knowledge, this is the first demonstration of Bcl2’s role in carcinogenesis well beyond apoptosis regulation to that of “master”
oncogene. Our in vivo data (Figures 5A-B) confirm this assertion. We show that
Cr(VI)-transformed BEAS-Cr cells form large tumors in nude mice, whereas
control BEAS-2B cells do not. This is the first report of Cr(VI)-transformed cells
exhibiting such in vivo properties. Furthermore, downregulation of Bcl-2 led to a
substantial reduction of tumor volume in BEAS-Cr derived tumors. This
mechanistic feature was nearly identical in human lung cancer H460 cells’
derived tumors, indicating a potential shared mechanism between laboratory
Cr(VI)-induced carcinogenesis and human lung cancer.
Finally, Ingenuity Pathways Analysis revealed the known Bcl-2-interactome
containing 56 molecules and 56 relationships identified as of IPA v8.6 (Figure
6B). Given that we were interested in mechanisms underlying the effects
observed following the downregulation of Bcl-2, we chose to focus on Ingenuity’s
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output of known downstream effectors of Bcl-2-interactome (Figure 6C). Did any
of the molecules listed have a link to regulation of tumor-associated properties
such as proliferation, transformation, migration, invasion and colony formation?
Analysis of Ingenuity Knowledge Base (IKB) strongly suggests YES. Out of all
downstream Bcl-2 effectors, nucleus-localized constituents strongly argue that
Bcl-2’s role in carcinogenesis exceeds that of apoptosis regulation in line with our
observations. Cyclin-dependent kinases 1 and 2 (CDK1&2) regulate cell cycle
progression, cellular motility and proliferation according to IKB summary of over
6,000 categorized literature findings. Their role in carcinogenesis is well
established. Next, telomerase (TERT) is an established positive regulator of cell
proliferation, immortalization and transformation. Its role in carcinogenesis is
widely accepted. Of interest, RAD9A, implicated in the regulation of colony
formation also appears in the IPA’s output. Relative to its “neighbors”, it is a less
studied protein with only 380 categorized literature findings in the IKB. Lastly,
vascular endothelial growth factor (VEGF) is a well established positive regulator
of angiogenesis and is a downstream target of Bcl-2. Its role in Cr(VI)-induced
carcinogenesis has not been demonstrated but is implicated by our study.
In conclusion, evidence presented in this report suggests Bcl-2’s role in
carcinogenesis is much more than apoptosis evasion to that of apoptosisproliferation network hub regulator. Animal and in vitro data support its role in
Cr(VI)-induced tumorigenesis and malignant transformation. The reported
experimental models may be used to aid mechanistic studies of other
carcinogens.

	
  

66	
  

FIGURE 1. Cell growth and colony formation capacities of BEAS-2B, BEAS-Cr and H460
5

cells. A, BEAS-2B, BEAS-Cr and H460 cells (1x10 cells) were seeded on 60-mm cell culture
o

dishes and were incubated at 37 C in a 5% CO2 incubator. At the indicated times, cells were
trypsinized and analyzed for cell number using an electronic cell counter. B, Representative light
micrographs of BEAS-2B, BEAS-Cr and H460 cells in culture at 96 h are shown. C, BEAS-2B,
4

BEAS-Cr and H460 cells (3x10 cells) were seeded on 0.5% agar plates and were incubated at
o

37 C in a 5% CO2 incubator. After 2 weeks, colony formation capacity was scored under a light
microscope. D, Representative micrographs of colonies formed by BEAS-2B, BEAS-Cr and H460
cells on soft agar are shown. Values are mean ± S.D. (n = 4). *p < 0.05 versus passage-control
BEAS-2B cells.
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FIGURE 2. In vitro relative malignant phenotype capacities of BEAS-2B, BEAS-Cr and H460
5

cells. A, BEAS-2B, BEAS-Cr and H460 cells (1x10 cells) were added to Transwell inserts coated
with Matrigel and incubated for 24 h. Invading cells were stained and counted under a light
microscope. Plots show relative invasion of BEAS-2B, BEAS-Cr and H460 cells. B,
Representative micrographs of cells stained for invasion are shown. C, Confluent monolayers of
BEAS-2B, BEAS-Cr and H460 cells were wounded, and the cells were allowed to migrate for 24
h. Wound space was visualized under a phase-contrast microscope and analyzed by comparing
the relative change in wound space as compared to control cell monolayers. D, Representative
micrographs of cells migrating from the wound edge are shown. Values are mean ± S.D. (n = 4).
*p < 0.05 versus passage-control BEAS-2B cells.
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FIGURE 3. Bcl-2 expression and response to Cr(VI) treatment in BEAS-2B, BEAS-Cr and
H460 cells. A, Endogenous Bcl-2 levels in BEAS-2B, BEAS-Cr and H460 cells determined by
Western blotting. Densitometry was performed to determine the relative Bcl-2 levels after
reprobing the membrane with β-actin antibody. B, Cells were either left untreated or treated with
Cr(VI) (10, 20 µM) for 12 h. Cell lysates were prepared and analyzed for Bcl-2 by Western
#

blotting. Values are mean ± S.D. (n = 4). *p < 0.05 versus passage-control BEAS-2B cells; p <
0.05 versus non-treated control of the respective cells.
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FIGURE 4. Effect of Bcl-2 knockdown on tumor-associated properties in vitro. A. Bcl-2
knockdown experiments were performed in BEAS-Cr and H460 cells by infecting the cells with
Bcl-2 shRNA (shBcl-2) viral particles or control shRNA (shCon) particles as described in
“Materials and Methods”. Clonal selection and Bcl-2 expression were performed to identify
mutants with downregulated Bcl-2. B, Effect of Bcl-2 on in vitro cell growth of the respective cell
5

o

lines and their mutants. Cells (1x10 cells) were seeded and incubated at 37 C for 96 h, after
4

which they were analyzed for cell number. C, Cells (3x10 cells) were seeded on soft agar plates
and the colonies were scored after 2 weeks. D, Invasion assays were performed using Transwell
invasion chambers as described. E, Cell migration was determined by wound assay as described.
Values are mean ± S.D. (n = 3). *p < 0.05 versus passage-control BEAS-2B cells or shCon cells.
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FIGURE 5. Effect of Bcl-2 knockdown on tumor-associated properties in vivo. A, Mice were
6

injected subcutaneously with 1x10 passage-control BEAS-2B, BEAS-Cr, or shBcl-2 BEAS-Cr
mutant cells. Tumor formation was determined at 14 d post-injection. Representative photographs
are shown. B, Mice were similarly injected with control BEAS-2B, H460, or shBcl-2 H460 cells.
Tumor formation and representative micrographs at 14 d post-injection are shown. Data are
means ± S.D. (n = 4). *p < 0.05 vs. passage-control BEAS-2B cells.
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FIGURE 6. Ingenuity Pathways Analysis software output for the Bcl-2 interactome. A, Initial
IPA query for the Bcl-2-interactome. 741 molecules were reported (as of IPA v8.6, October 5,
2010). B, Bcl-2-interactome filtered for interactions reported in humans only and presented by
cellular localization. 56 molecules were reported to interact either directly or indirectly. C,
Downstream components of human Bcl-2-interactome. 20 molecules were reported to date.
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OVERALL CONCLUSIONS

•

Cr(VI) induces apoptosis in cancerous H460 cells and non-cancerous BEAS2B cells in a dose dependent manner.

•

Cancerous H460 cells exhibit 4-fold native resistance to Cr(VI)-induced
apoptosis.

•

The native apoptosis resistance of cancerous H460 cells is abrogated when
oxidative phosphorylation-only metabolism is forced.

•

ROS play a key role in Cr(VI)-induced apoptosis signaling.

•

The primary, apoptosis relevant, source of ROS is mitochondrion.

•

mROS intensity is increased in cancerous H460 cells but not in noncancerous BEAS-2B cells when oxidative phosphorylation-only metabolism is
forced.

•

Inhibition of mROS as well as outer mitochondrial membrane signaling (via
Bcl-2) leads to inhibition of Cr(VI)-induced apoptosis.

•

Prolonged exposure of non-cancerous BEAS-2B cells to sub-lethal Cr(VI)
dose leads to transformation and evolution of malignant phenotype.

•

Cell growth, colony formation, migration and invasion capacities of
transformed BEAS-2B (BEAS-Cr) cells are substantially elevated in vitro.

•

Stable and selective knockdown of Bcl-2 leads to significant reduction in
tumor-associated properties in vitro in human lung cancer H460 and
laboratory evolved malignant BEAS-Cr cells.

•

Stable and selective knockdown of Bcl-2 leads to comparable reduction in
tumor-associated properties in vivo in human lung cancer H460 and
laboratory evolved malignant BEAS-Cr cells.

•

Cr(VI)-induced malignant transformation of human lung epithelial cells is of
clear relevance to human exposure and validates human lung epithelial cells
as a direct target for Cr(VI)-induced carcinogenesis.
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